Indoco Remedies Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹323
- Today's High:
- ₹343.5
- Open Price:
- ₹328.1
- 52W Low:
- ₹307
- 52W High:
- ₹423.1
- Prev. Close:
- ₹324.15
- Volume:
- 158201
Company Statistics
- Market Cap.:
- ₹23.05 billion
- Book Value:
- 77.959
- Revenue TTM:
- ₹11.65 billion
- Operating Margin TTM:
- 9.2%
- Gross Profit TTM:
- ₹7.47 billion
- Profit Margin:
- 4.9%
- Return on Assets TTM:
- 5%
- Return on Equity TTM:
- 8.25%
Company Profile
Indoco Remedies Limited had its IPO on under the ticker symbol 532612.
The company operates in the Healthcare sector and Drugs - Generic industry. Indoco Remedies Limited has a staff strength of 5,500 employees.
Stock update
Shares of Indoco Remedies Limited opened at ₹328.1 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹323 - ₹343.5, and closed at ₹339.85.
This is a +4.84% increase from the previous day's closing price.
A total volume of 158,201 shares were traded at the close of the day’s session.
In the last one week, shares of Indoco Remedies Limited have increased by +8.98%.
Indoco Remedies Limited's Key Ratios
Indoco Remedies Limited has a market cap of ₹23.05 billion, indicating a price to book ratio of 3.2668 and a price to sales ratio of 2.0678.
In the last 12-months Indoco Remedies Limited’s revenue was ₹11.65 billion with a gross profit of ₹7.47 billion and an EBITDA of ₹1.58 billion. The EBITDA ratio measures Indoco Remedies Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Indoco Remedies Limited’s operating margin was 9.2% while its return on assets stood at 5% with a return of equity of 8.25%.
In Q3, Indoco Remedies Limited’s quarterly earnings growth was a positive 227.1% while revenue growth was a positive 12%.
Indoco Remedies Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 41.129
- PEG
Its diluted EPS in the last 12-months stands at ₹6.195 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Indoco Remedies Limited’s profitability.
Indoco Remedies Limited stock is trading at a EV to sales ratio of 2.2137 and a EV to EBITDA ratio of 14.3285. Its price to sales ratio in the trailing 12-months stood at 2.0678.
Indoco Remedies Limited stock pays annual dividends of ₹0.3 per share, indicating a yield of 0.12% and a payout ratio of 4.84%.
Balance sheet and cash flow metrics
- Total Assets
- ₹16.58 billion
- Total Liabilities
- ₹4.25 billion
- Operating Cash Flow
- ₹-2081800000.00
- Capital Expenditure
- ₹2.07 billion
- Dividend Payout Ratio
- 4.84%
Indoco Remedies Limited ended 2024 with ₹16.58 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹16.58 billion while shareholder equity stood at ₹10.28 billion.
Indoco Remedies Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹4.25 billion in other current liabilities, 184300000.00 in common stock, ₹10.10 billion in retained earnings and ₹900000.00 in goodwill. Its cash balance stood at ₹0 and cash and short-term investments were ₹173.40 million. The company’s total short-term debt was ₹0 while long-term debt stood at ₹1.44 billion.
Indoco Remedies Limited’s total current assets stands at ₹8.08 billion while long-term investments were ₹0 and short-term investments were ₹40.00 million. Its net receivables were ₹3.51 billion compared to accounts payable of ₹0 and inventory worth ₹3.26 billion.
In 2024, Indoco Remedies Limited's operating cash flow was ₹-2081800000.00 while its capital expenditure stood at ₹2.07 billion.
Comparatively, Indoco Remedies Limited paid ₹0.05 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹339.85
- 52-Week High
- ₹423.1
- 52-Week Low
- ₹307
- Analyst Target Price
- ₹
Indoco Remedies Limited stock is currently trading at ₹339.85 per share. It touched a 52-week high of ₹423.1 and a 52-week low of ₹423.1. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹326.24 and 200-day moving average was ₹346.96 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 6080.4% of the company’s stock are held by insiders while 1651.2% are held by institutions.
Frequently Asked Questions About Indoco Remedies Limited
Similar Industry Stocks (Drugs - Generic)
Most Active
Top Gainers
Top Losers
About
Indoco Remedies Limited manufactures and sells formulations and active pharmaceutical ingredients in India and internationally. The company offers respiratory products, such as Karvol Plus, Febrex Plus, and Tuspel; stomatologicals products that include Sensodent-K, Sensoform, Sensodent-KF, Snowdent, Kidodent, Rexidin Plus, and Dentogel; gastro intestinal products, such as Carmicide, Cyclopam, Carmicide Drops, Cyclomeff, and Nosic; pain/analgesics products that include Lignox and T-lac; and opthalmological products, such as Renolen, Homide, Tobaren DM, and Mofloren-D. It also provides vitamins/minerals/nutrients that include Methycal, MCBM 69, SM Fibro, Durashape, Trucharge, and Apispur; Urology products, such as Cital, Cital UTI, and Cital-H; Cloben-G and Scabex for derma; ATM for anti-invectives; Otorex for otologicals; Obi X and KG-Low for anti-obesity; Hemsyl for blood related; Dexoren for Opthal/Otologicals; and Vepan, bactogard, and Oxipod for anti-infectives. In addition, the company offers PGVISC eye drops; Aziltence for cardiac therapy; and D-Chiro for gynaec therapy. Further, it provides analytical services, such as impurity profile, particle size analysis, heavy metal analysis, polymorphism, compatibility, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and validation services. Additionally, the company offers services that include architectural design, lighting, mechanical and utility engineering, project and construction management, electrical, control system, piping, structural design, data transfer system, and process engineering. It serves general practitioners, pediatricians, consultant physicians, dentists, cardiologists, diabetologists, endocrinologists, and nephrologists. The company was formerly known as Indo Continental Trading Company. Indoco Remedies Limited was founded in 1945 and is based in Mumbai, India.